NYM074 是一种碳酸酐酶 IX (CAIX) 配体,可特异性结合人源 CAIX 以实现靶向放射性核素递送,并支持双重放射性标记——用 68Ga 标记可用于正电子发射断层扫描 (PET) 成像,用 177Lu 标记可用于放射性核素相关应用,因此可用于透明细胞肾细胞癌的研究。
NYM074
产品编号: MS-O10131 分子式: C41H59N11O12S2 分子量: 962.10
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

NYM074 是一种碳酸酐酶 IX (CAIX) 配体,可特异性结合人源 CAIX 以实现靶向放射性核素递送,并支持双重放射性标记——用 68Ga 标记可用于正电子发射断层扫描 (PET) 成像,用 177Lu 标记可用于放射性核素相关应用,因此可用于透明细胞肾细胞癌的研究。

生物实验数据

生物活性 NYM074 is a carbonic anhydrase IX (CAIX) ligand that specifically binds to human CAIX to enable targeted radionuclide delivery and supports dual radiolabeling, allowing 68Ga labeling for positron emission tomography (PET) imaging and 177Lu labeling for radionuclide-related applications, and can therefore be used for research on clear cell renal cell carcinoma.
IC50 & Target

hCA IX

 

体外研究
(In Vitro)

NYM074 (0.5-500 nM;240 s) 在体外 SPR 实验中,相较于人 CAII 和 CAXII,以高选择性亲和力结合重组人 CAIX (Kd = 0.65 nM)。
NYM074 经放射性标记为 [68Ga]Ga-NYM074 后,在体外实验中可被 CAIX 阳性 OS-RC-2 细胞选择性摄取;当加入 100 倍过量的未标记 NYM074 时,其摄取量显著降低,而 CAIX 阴性 PC-3 细胞的摄取量极低。

体内研究
(In Vivo)

NYM074 (2 mCi;静脉注射;单剂量给药,或间隔 7 天给药 2 次;最长观察 30 天) 经 177Lu 标记后,在 OS-RC-2 肾透明细胞癌异种移植小鼠中实现 73.90% 的最大肿瘤生长抑制率,且耐受性良好。
NYM074 (0.1 mCi;静脉注射;单剂量) 经 68Ga 标记后,在 OS-RC-2 肾透明细胞癌异种移植小鼠中于 60 分钟时达到 9.57 %ID/g 的肿瘤摄取峰值。
NYM074 (0.3 mCi;静脉注射;单次给药) 经 177Lu 标记后,在 OS-RC-2 肾透明细胞癌异种移植小鼠中表现出较高且持久的肿瘤摄取,4 小时时肿瘤摄取量达 29.15 %ID/g,计算得出的肿瘤吸收剂量为 296 mGy/MBq。
NYM074 (28.57 μg/kg;静脉注射;单次给药) 经 68Ga 标记后,在健康 ICR 小鼠体内表现出 3.3 小时的半衰期,主要经肾脏排泄,其中肾脏和肝脏的摄取量最高。
NYM074 (2 mCi;静脉注射;单剂量;14 天) 经 177Lu 标记后,未在健康 ICR 小鼠的主要器官中引发显著的组织病理学变化。
NYM074 (0.3 mCi;静脉注射;单剂量) 经 177Lu 标记后,在健康 ICR 小鼠体内以肾脏排泄为主,在肾脏和肝脏中的摄取量最高,骨骼摄取量极低,表明其具有体内稳定性。

Animal Model: BALB/c nude mice (female, 6-8 weeks, 18-22 g, subcutaneously inoculated with OS-RC-2 tumor cells)
Dosage: 2 mCi
Administration: i.v.; single dose or two doses with 7-day interval; up to 30 days
Result: Resulted in a final tumor volume of 1248.89 mm3, a T/C ratio of 65.24%, and a tumor growth inhibition (TGI) of 40.47% compared to the saline control group.
Resulted in a final tumor volume of 547.55 mm3, a T/C ratio of 25.33%, and a TGI of 73.90% (P < 0.001 vs. saline).
Showed stable body weights with <5% loss, with no significant difference from the vehicle control group.
Animal Model: BALB/c nude mice (female, 6-8 weeks, 18-22 g, subcutaneously inoculated with OS-RC-2 tumor cells)
Dosage: 0.1 mCi
Administration: i.v.; single dose
Result: Showed time-dependent tumor uptake, peaking at 9.57 %ID/g at 60 minutes post-injection.
Reached a tumor-to-muscle ratio of 8.25 at 60 minutes.
Reduced tumor uptake by 78.69% with co-injection of 10 mg/kg acetazolamide, confirming specific CAIX targeting.
Decreased renal uptake over time from 19.85 %ID/g at 10 minutes to 13.74 %ID/g at 120 minutes.
Animal Model: BALB/c nude mice (female, 6-8 weeks, 18-22 g, subcutaneously inoculated with OS-RC-2 tumor cells)
Dosage: 0.3 mCi
Administration: i.v.; single dose
Result: Showed sustained tumor retention, with ex vivo uptake of 29.15 %ID/g at 4 hours and 3.28 %ID/g at 48 hours post-injection.
Achieved a calculated tumor absorbed dose of 296 mGy/MBq.
Declined liver and kidney radioactivity significantly over time.
Animal Model: ICR mice (6-week-old)
Dosage: 28.57 μg/kg
Administration: i.v.; single dose
Result: Showed highest uptake in kidneys (11.31 %ID/g at 15 minutes; 13.97 %ID/g at 60 minutes; 13.05 %ID/g at 120 minutes; 11.04 %ID/g at 240 minutes) and liver (9.63 %ID/g at 15 minutes; 9.70 %ID/g at 60 minutes; 9.76 %ID/g at 120 minutes; 8.47 %ID/g at 240 minutes).
Achieved a half-life (T1/2) of 3.3 hours, moderate clearance rate (CL_obs = 0.53 (L/h)/kg), and mean residence time (MRT(0-inf)_obs) of 5.03 hours.
Reached effective absorbed doses for male/female mice of 0.012/0.015 mSv/MBq.
Animal Model: ICR mice (healthy adult, 20-25 g, half male/half female)
Dosage: 2 mCi
Administration: i.v.; single dose; 14 days
Result: Revealed intact tissue architecture and normal cellular morphology in kidneys, liver, spleen, lungs, and heart.
Showed no significant inflammation, necrosis, fibrosis, hemorrhage, or other treatment-related pathological alterations.
Animal Model: ICR mice
Dosage: 0.3 mCi
Administration: i.v.; single dose
Result: Showed highest uptake in kidneys (52.78 %ID/g at 1 hour; 34.36 %ID/g at 6 hours; 5.67 %ID/g at 24 hours; 4.64 %ID/g at 48 hours) and liver (34.25 %ID/g at 1 hour; 28.53 %ID/g at 6 hours; 1.93 %ID/g at 24 hours; 0.47 %ID/g at 48 hours).
Showed uptake in brain, spleen, bone, and bone marrow of <0.25 %ID/g at all time points.
Reached whole-body effective doses for male/female mice of 0.026/0.035 mSv/MBq.

化学信息

分子量 962.10
分子式 C41H59N11O12S2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础